Flavin adenine dinucleotide API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Flavin adenine dinucleotide API 146-14-5?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Flavin adenine dinucleotide. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Flavin adenine dinucleotide
- Synonyms:
- Adenosine 5'-(trihydrogen pyrophosphate), 5'-5'-ester with riboflavine , adenosine 5'-[3-(riboflavin-5'-yl) dihydrogen diphosphate] , FAD , Flavin-Adenine Dinucleotide , Flavine adenine dinucleotide , Riboflavin 5'-(trihydrogen diphosphate), 5'-5'-ester with adenosine , Riboflavin 5'-adenosine diphosphate
- Cas Number:
- 146-14-5
- DrugBank number:
- DB03147
- Unique Ingredient Identifier:
- ZC44YTI8KK
General Description:
Flavin adenine dinucleotide, identified by CAS number 146-14-5, is a notable compound with significant therapeutic applications. A condensation product of riboflavin and adenosine diphosphate. The coenzyme of various aerobic dehydrogenases, e.g, D-amino acid oxidase and L-amino acid oxidase. (Lehninger, Principles of Biochemistry, 1982, p972) Flavin adenine dinucleotide is approved for use in Japan under the trade name Adeflavin as an ophthalmic treatment for vitamin B2 deficiency.
Indications:
This drug is primarily indicated for: Used to treat eye diseases caused by vitamin B2 deficiency, such as keratitis and blepharitis. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Toxicity:
Classification:
Flavin adenine dinucleotide belongs to the class of organic compounds known as flavin nucleotides. These are nucleotides containing a flavin moiety. Flavin is a compound that contains the tricyclic isoalloxazine ring system, which bears 2 oxo groups at the 2- and 4-positions, classified under the direct parent group Flavin nucleotides. This compound is a part of the Organic compounds, falling under the Nucleosides, nucleotides, and analogues superclass, and categorized within the Flavin nucleotides class, specifically within the None subclass.
Categories:
Flavin adenine dinucleotide is categorized under the following therapeutic classes: Adenine Nucleotides, Biological Factors, Coenzymes, Enzymes and Coenzymes, Flavins, Heterocyclic Compounds, Fused-Ring, Nucleic Acids, Nucleotides, and Nucleosides, Nucleotides, Pigments, Biological, Pteridines, Purine Nucleotides, Purines, Ribonucleotides, Vitamin B Complex, Vitamins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Flavin adenine dinucleotide is a type of Enzyme Replacements/modifiers
Enzyme replacements/modifiers are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) utilized in the treatment of various enzyme-related disorders. Enzymes play a vital role in the normal functioning of the body by catalyzing specific biochemical reactions. However, in certain medical conditions, the body may lack or produce dysfunctional enzymes, leading to serious health complications.
Enzyme replacement therapy (ERT) involves administering exogenous enzymes to compensate for the enzyme deficiency in patients. These enzymes are typically derived from natural sources or produced using recombinant DNA technology. By introducing these enzymes into the body, they can effectively substitute the missing or defective enzymes, thereby restoring normal metabolic processes.
On the other hand, enzyme modifiers are API substances that regulate the activity of specific enzymes within the body. These modifiers can either enhance or inhibit the enzyme's function, depending on the therapeutic objective. By modulating enzyme activity, these APIs can restore the balance of enzymatic reactions, leading to improved physiological outcomes.
Enzyme replacements/modifiers have shown remarkable success in treating various genetic disorders, such as Gaucher disease, Fabry disease, and lysosomal storage disorders. Additionally, they have demonstrated potential in managing enzyme deficiencies associated with rare diseases and certain types of cancer.
The development and production of enzyme replacements/modifiers involve rigorous research, formulation optimization, and adherence to stringent quality control measures. Pharmaceutical companies invest substantial resources in developing these APIs to ensure their safety, efficacy, and compliance with regulatory standards.
Overall, enzyme replacements/modifiers represent a vital therapeutic category in modern medicine, offering hope and improved quality of life for patients with enzyme-related disorders.
